MOUNTAIN VIEW, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Locus Technologies, the sustainability and Environmental Health and Safety (EHS) compliance software leader, announced the release of Locus ...
RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Locus Biosciences, a clinical-stage biotechnology company, announced today the completion of its Phase 1b clinical trial of LBP-EC01, a ...
Locus Pharmaceuticals Completes $30.2 Million Financing Round Locus Pharmaceuticals, Inc., a computationally based drug design and development company, announced today that it has closed on a $30.2 ...
Locus Biosciences (Locus) has begun treating the first patient in its phase 2/3 trial of LBP-EC01, in partnership with the Biomedical Advanced Research and Development Authority (BARDA), for the ...
Locus Biosciences is expecting more growth in 2022, as the gene-editing company strives to provide alternatives to the pressing issue of drug-resistant bacteria. Fresh off positive Phase 1 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results